The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
HOME > COMMENTARY
COMMENTARY
- Recent Topics in Hopeful Drugs and Candidates with Unique Mode of Action: 2
March 26, 2012
- Recent Topics in Hopeful Drugs and Candidates with Unique Mode of Action: 1
March 19, 2012
- Indications for Boosted Alliances, Acquisitions in Vaccine Business among Major Japanese Companies
March 13, 2012
- Further Provisions Required – One Year since the Great East Japan Earthquake
March 12, 2012
- Major US, European Drug Makers Report Growth in 2011 as Patent Cliff Approaches
March 5, 2012
- Will Wholesalers Be Able to Succeed at Reform This Time?
February 20, 2012
- Industry Should Prepare Arguments in Advance to Ward Off Possibility of 3 Consecutive NHI Price Revisions
January 23, 2012
- Will New Drug Makers Dominate Domestic Biosimilars Market?
December 26, 2011
- Pressure Mounting for Additional NHI Price Cut for Long-listed Drugs
December 12, 2011
- “Drug Discovery Support Organization” Faces Doubts: Can It Pick Winners?
November 28, 2011
- Perpetuation of Premium for New Drug Development Faces Hurdles
November 14, 2011
- Further Research Needed to Advance the Use of Regulatory Science in Regulatory Affairs
November 14, 2011
- Impact on Japanese Pharmaceutical Companies Unavoidable: TPP Negotiations
October 19, 2011
- Pinning Hope on Academia in Seeking a Radical Cure for AD
October 10, 2011
- New Ideas Needed to Address “Insurance Lag” for GE Drug Makers That Submit Applications Based on Info. in Public Domain
October 3, 2011
- Discussions on Amendment of PAL Now in Final Stages
October 3, 2011
- Korosho Revises GL for Drafting, Distributing Drug Safety Information
September 5, 2011
- Final Decision on Avastin's Indication for Breast Cancer Must Satisfy the Public
August 29, 2011
- Why Eisai's Novel Anticancer Agent Halaven Received the Highest Ever Operating Profit Rate
August 8, 2011
- Current Promising Drug Candidates with a New Mode of Action
August 8, 2011
ページ
The health ministry’s key expert panel on February 15 agreed on the need to consolidate the Japanese generic sector to…
“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…